基于支持向量机的急性出血性脑卒中早期预后模型的建立与评价

来源 :南京医科大学学报(自然科学版) | 被引量 : 0次 | 上传用户:sxhainan
下载到本地 , 更方便阅读
声明 : 本文档内容版权归属内容提供方 , 如果您对本文有版权争议 , 可与客服联系进行内容授权或下架
论文部分内容阅读
目的:比较支持向量机(support vector machine,SVM)和传统的Logistic回归构建的急性出血性脑卒中(intracerebral hemorrhage,ICH)早期预后判别模型的预测性能,探索急性ICH预后研究的新方法。方法 :收集急性ICH患者339例,随访观察21 d时的临床转归情况。应用随机数字法以3∶1的比例分为两组,一组作为训练样本用于筛选变量和建立预测模型,计254例;另一组作为验证样本,用于评价模型预测效果,计85例。建模方法采用SVM和常规统计方法中的Logistic回归。结果:通过对85例ICH患者的预测判别验证,SVM1的预测分类能力在4个模型为最强,4个模型预测的准确率和Youden指数分别为:Logistic回归:72.9%(62.0%~81.7%)、0.441(0.249~0.633);SVM1:82.4%(72.3%~89.5%)、0.632(0.465~0.799);SVM2:78.8%(68.4%~86.6%)、0.557(0.379~0.735);SVM3:78.8%(68.4%~86.6%)、0.563(0.385~0.741)。结论:采用SVM能较好地判断急性ICH患者的早期预后,其效能优于Logistic回归模型。 OBJECTIVE: To compare the predictive performance of the early prognosis model of acute hemorrhagic stroke (ICH) with support vector machine (SVM) and traditional Logistic regression, and to explore a new method for the prognosis of acute ICH. Methods: A total of 339 patients with acute ICH were collected and followed up for 21 days. Random number method was used to divide the patients into three groups according to the ratio of 3:1. One group was used as the training sample to select the variables and establish the predictive model, with 254 cases in total. The other group was used as the verification sample to evaluate the predictive effect of the model. . The modeling method uses Logistic regression in SVM and conventional statistical methods. Results: The predictive classification of 85 ICH patients showed that SVM1 had the strongest prediction classification ability among the four models. The prediction accuracy of the four models and the Youden index were: Logistic regression: 72.9% (62.0% -81.7% ), 0.441 (0.249-0.633), SVM1: 82.4% (72.3% -89.5%), 0.632 (0.465-0.799), SVM2: 78.8% (68.4% -86.6%), 0.557 (0.379-0.735) % (68.4% ~ 86.6%), 0.563 (0.385 ~ 0.741). Conclusion: The SVM can be used to judge the early prognosis of patients with acute ICH better than Logistic regression model.
其他文献
阐述抑制蛋白酶体是癌症治疗的一种新方法.波替单抗(商品名:万珂)是第一个被批准临床应用的蛋白酶体抑制剂,临床前试验表明其对许多肿瘤细胞株有效;Ⅰ期临床试验确定了最佳剂量与可处理的毒性;两个Ⅱ期试验(SUMMIT与CREST)证明万珂治疗复发和(或)难治的多发性骨髓瘤(MM)安全有效;Ⅲ期APEX试验比较万珂与大剂量地塞米松治疗复发的MM证实万珂能提高有效率、缓解持续时间和总生存期.研究者探索万珂与
目的观察法舒地尔联合尼莫地平对蛛网膜下腔出血后脑血管痉挛患者近期及远期疗效。方法 87例蛛网膜下腔出血后脑血管痉挛患者随机分为对照组43例与试验组44例。2组均给予常规